Robert Wessman, the Chairman of Lotus Pharmaceuticals Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), has announced the purchase of 300,000 shares, at an average NT$52.1 per share, in Lotus today. This acquisition has been made through investment company, Aztiq Lux Sarl.
Robert Wessman commented: “The world is going through unprecedented times due to the Covid-19 virus. The impact of Covid-19 on the world stock market is severe and, in my opinion, the current Lotus share price does not reflect the long-term prospects and potential of the company.”
“2020 is expected to be an exciting year for Lotus after reporting record revenues and profitability in 2019. We have positioned Lotus around the development and commercialization of high quality oncology medicines and complex generic pharmaceuticals that we will continue to bring to patients and partners around the world. With further investments in our manufacturing facility in Taiwan and a commitment to further diversify and strengthen our product offering, we are well positioned to deliver long-term shareholder value,” Wessman added.